Single-cell sequencing reveals effects of chemotherapy on the immune landscape and TCR/BCR clonal expansion in a relapsed ovarian cancer patient

Yan-Yu Ren, Runrong Li, Hanxiao Feng, Jieying Xie, Lin Gao, Shuai Chu, Yan Li, Fanliang Meng, Yunshan NingFrontiers in Immunology 2022 · DOI

TL;DR

This study uses single-cell sequencing to dissect the complex immune landscape of a relapsed, chemo-resistant ovarian cancer patient. It reveals how chemotherapy reshapes the tumor microenvironment, leading to an immunosuppressive state and altered T and B cell responses, offering insights for new therapeutic strategies.

What Problem Does This Paper Address?

High-grade serous ovarian cancer (HGSOC) is notorious for its recurrence and resistance to chemotherapy, making it a leading cause of cancer death. While the tumor microenvironment (TME) is known to play a crucial role, its specific dynamics in relapsed, chemo-resistant patients remain poorly understood. This paper aims to shed light on how chemotherapy impacts the cellular composition and immune cell behavior within the TME, particularly in the context of a patient who has developed resistance. Understanding these intricate interactions is vital for developing more effective treatments.

Methods

The researchers employed a multi-pronged approach:

  • Single-cell RNA sequencing (scRNA-seq): This was the core technique, allowing them to analyze the gene expression of individual cells from tumor tissue, ascites fluid, and peripheral blood. This provides a high-resolution view of cellular heterogeneity and function.
  • TCR/BCR sequencing: Paired with scRNA-seq, this technique allowed for the analysis of T cell receptor (TCR) and B cell receptor (BCR) repertoires. This is crucial for understanding the diversity and clonal expansion of immune cells, which are key to adaptive immunity.
  • Immunohistochemistry (IHC): Used to confirm the presence and location of specific cell types, like CD8+ T cells, within the tumor tissue.
  • Flow Cytometry: Employed to analyze immune cell populations in peripheral blood before and after chemotherapy.
  • Bioinformatics Analysis: A suite of computational tools (e.g., Seurat, CellChat, inferCNV) was used for data processing, cell type identification, clustering, differential gene expression analysis, cell-cell communication inference, and copy number variation (CNV) analysis.

Datasets

The study utilized samples from a single patient with relapsed, chemo-resistant HGSOC, including:

  • Solid tumor tissue
  • Ascites fluid
  • Peripheral blood mononuclear cells (PBMCs) collected at different time points during chemotherapy.

Additionally, they integrated publicly available scRNA-seq data from five other HGSOC patients (GEO accession number GSE154600) to compare chemo-resistant and chemo-sensitive profiles.

Key Insights and Ideas

  • Ascites as an Immunosuppressive Hub: The ascites fluid harbored an immunosuppressive microenvironment, characterized by myeloid-derived suppressor cell (MDSC)-like cells and hypo-metabolic γδT cells, suggesting it plays a significant role in promoting recurrence and chemoresistance.
  • Chemotherapy Induces T Cell Exhaustion and Senescence: Peripheral CD8+ effector T cells showed signs of chemotherapy-induced senescence and exhaustion, indicating a compromised anti-tumor response.
  • TCR/BCR Repertoire Dynamics: Chemotherapy significantly altered the TCR and BCR repertoires. While TCR clonal expansion in CD8+ T cells showed some conservation, BCR clonal expansion was extensive, suggesting a broad immune response to chemotherapy-induced changes.
  • Tumor Cell Heterogeneity and Chemoresistance: The tumor cells themselves exhibited heterogeneity, with a specific subpopulation (EC3) showing high expression of chemotherapy resistance genes and being in proliferative phases, potentially contributing to resistance.
  • IFN Signature as a Potential Prognostic Marker: High expression of interferon (IFN)-associated genes in tumor cells was linked to better prognosis in TCGA data, suggesting a potential role for immune response in predicting outcomes.

Key Results

  • Cellular Composition: Identified distinct cell types including tumor cells, myeloid cells, NK/T cells, B cells, and cancer-associated fibroblasts (CAFs) in tumor and ascites. Immune cells were more abundant in ascites than in tumor tissue.
  • Tumor Cell Subclusters: Nine epithelial tumor cell subclusters were identified, with one (EC3) exhibiting markers associated with chemotherapy resistance and hyperproliferation.
  • Myeloid Cell Phenotypes: Myeloid cells in ascites and tumor showed characteristics of immunosuppressive phenotypes, including MDSC-like and M2-like macrophages.
  • T Cell Subsets: Identified various T cell subsets, including activated, memory, naive, regulatory T cells (Tregs), cytotoxic T lymphocytes (CTLs), MAIT cells, and γδT cells. Ascites-derived T cells showed signs of impaired immune function.
  • Chemotherapy Effects on PBMCs: Post-chemotherapy, an increase in NK cells was observed. CD8+ T cells showed signs of exhaustion and senescence, while CD4+ T cells exhibited a more activated profile.
  • TCR/BCR Repertoire Changes: Chemotherapy led to significant changes in TCR and BCR clonal expansion, with a notable increase in unique clonotypes and altered repertoire space occupation.

Limitations and Future Work

  • Single Patient Study: The findings are based on a single patient, limiting generalizability. Future work should involve larger cohorts of relapsed, chemo-resistant patients.
  • In Vitro and In Vivo Validation: The study relies heavily on observational data. Further in vitro and in vivo experiments are needed to elucidate the precise mechanisms of chemoresistance.
  • Dual Targeting Strategies: The authors suggest that targeting both tumor cell intrinsic properties and the TME simultaneously could be a promising strategy to overcome chemoresistance.
  • Novel Immunomodulatory Therapies: The findings provide a foundation for developing novel chemotherapy combinations with anti-senescence agents or other immunomodulatory strategies to improve clinical outcomes in HGSOC.

Summary updated

Abstract

Cancer recurrence and chemoresistance are the leading causes of death in high-grade serous ovarian cancer (HGSOC) patients. However, the unique role of the immune environment in tumor progression for relapsed chemo-resistant patients remains elusive. In single-cell resolution, we characterized a comprehensive multi-dimensional cellular and immunological atlas from tumor, ascites, and peripheral blood of a chemo-resistant patient at different stages of treatment. Our results highlight a role in recurrence and chemoresistance of the immunosuppressive microenvironment in ascites, including MDSC-like myeloid and hypo-metabolic γδT cells, and of peripheral CD8<sup>+</sup> effector T cells with chemotherapy-induced senescent/exhaustive. Importantly, paired TCR/BCR sequencing demonstrated relative conservation of TCR clonal expansion in hyper-expanded CD8<sup>+</sup> T cells and extensive BCR clonal expansion without usage bias of V(D)J genes after chemotherapy. Thus, our study suggests strategies for ameliorating chemotherapy-induced immune impairment to improve the clinical outcome of HGSOC.
BibTeX
@inproceedings{ren2022single,
  author = {Yan-Yu Ren and Runrong Li and Hanxiao Feng and Jieying Xie and Lin Gao and Shuai Chu and Yan Li and Fanliang Meng and Yunshan Ning},
  title = {{Single-cell sequencing reveals effects of chemotherapy on the immune landscape and TCR/BCR clonal expansion in a relapsed ovarian cancer patient}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.985187},
}
Figure